Servier to buy Day One Biopharmaceuticals for $2.5 billion
Servier will buy Day One Biopharmaceuticals for a total equity value of $2.5 billion. The companies announced the agreement on Friday to expand their reach.
The independent international pharmaceutical group Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals, Inc. for a total equity value of approximately $2.5 billion. The companies announced the transaction on Friday, highlighting a strategic move to consolidate resources within the oncology sector.
Under the terms of the agreement, the acquisition will integrate the clinical-stage biopharmaceutical company into the global operations of Servier. The deal reflects a significant valuation and underscores the growing demand for specialized therapeutic platforms in the biotech industry.
The transaction is expected to close following customary regulatory approvals and closing conditions. Both organizations have indicated that the merger will aim to accelerate the development of innovative treatments for patients facing severe medical challenges.
